Drug / Drugs / Boston blog main / Indiana blog main / National blog main / San Francisco / San Francisco blog main / San Francisco top stories / abaloparatide / Amgen / Biotech / clinical trials / Eli Lilly / FDA / Food and Drug Administration / Life Sciences / Osteoporosis / Radius Health / romosozumab / teriparatide / UCB

With New Data, Amgen Tries Again for FDA OK of Osteoporosis Drug

Posted on: Jul 14, 2018   |   Posted by: Biotech Mag

With New Data, Amgen Tries Again for FDA OK of Osteoporosis Drug

More than a year after the FDA rejected Amgen's experimental osteoporosis drug due to safety concerns, the Thousand Oaks, CA, company has teed up a new application. The Amgen...

Continue reading ...